



Edelris initiates a multi-target Research Agreement with Bayer

Lyon, January 25, 2022 - Edelris announced today that they have entered into a new agreement for the discovery of innovative and selective ligands on biological targets of interest for Bayer, focusing on addressing new modes of action for disease control in pilot projects.

« Bayer has been a long-standing client of Edelris and we are happy to have the possibility to make the difference with Bayer again! » stated Jean-Yves Ortholand, CEO at Edelris « We will have the opportunity to demonstrate that our technologies can help a leading and global crop protection organization finding meaningful active compounds of next generation. Our team is eager to continue our relationship with this collaboration! »

Edelris will activate EDEN (Edelris Discovery ENgine), combining its dedicated AS-MS (Affinity Selection-Mass Spectrometry) screening technologies and expertise based upon with its proprietary compound library of 2M lead-like members originating from Edelris' Keymical Space™.

The financial terms are not disclosed.

About Edelris

Edelris has been relentlessly bringing creative solutions to clients and partners from drug discovery organizations for the past 16 years, with a clear focus on Hit generation and Hit-to-Lead optimization. Edelris has pioneered the value of 3D, natural product-like compound collections for HTS and FBLD (Keymical Collections™ and Fragments), and offers track-proven medicinal chemistry and synthesis of explorative chemical libraries, encoded and non-encoded. Further to this, Edelris differentiates itself with EDEN (Edelris Discovery ENgine) based upon a 2 million proprietary compound collection (Keymical Space™) and AS-MS technologies. More info at www.edelris.com. and [LinkedIn](#).